Thus, combined targeting of MYC and checkpoint regulators such as CHEK1 might serve as a therapeutic means to improve outcomes in treatment of aggressive G3 MBs with CTDNEP1-deficiency. This evidence concerns the gene CHEK1 and Mobius syndrome.